Results 171 to 180 of about 2,039,151 (340)

Unveiling unique protein and phosphorylation signatures in lung adenocarcinomas with and without ALK, EGFR, and KRAS genetic alterations

Molecular Oncology, EarlyView.
Proteomic and phosphoproteomic analyses were performed on lung adenocarcinoma (LUAD) tumors with EGFR, KRAS, or EML4–ALK alterations and wild‐type cases. Distinct protein expression and phosphorylation patterns were identified, especially in EGFR‐mutated tumors. Key altered pathways included vesicle transport and RNA splicing.
Fanni Bugyi, Mirjam Balbisi, Simon Sugár, Lóránd Váncza, Eszter Regős, Ilona Kovalszky, Ibolya Laczó, Tünde Harkó, Gábor Kecskeméti, Zoltán Szabó, Judit Moldvay, László Drahos, Lilla Turiák   +12 more
wiley   +1 more source

STUDIES ON ANTIMICROBIAL SUBSTANCE B 44 P (STREPTOVARICIN) PRODUCED BY A STRAIN OF ACTINOMYCETES. II

, 1968
Hisaji Yamazaki
openalex   +2 more sources

Targeting of PTP4A3 overexpression sensitises HGSOC cells towards chemotherapeutic drugs

Molecular Oncology, EarlyView.
In HGSOC with normal KRAS expression, high PTP4A3 expression regulates autophagy activation. Conversely, in HGSOC with high KRAS expression, KRAS dictates autophagy control, and PTP4A3 is not required. When high PTP4A3 expression is inhibited, HGSOC cells are preferentially sensitised towards DNA‐damaging agents.
Ana López‐Garza, David James, Emma Creagh, James T. Murray   +3 more
wiley   +1 more source

Revisiting the role of Substance P and CGRPα. [PDF]

Elife
Cai W, Khoutorsky A.
europepmc   +1 more source

Function of Substance P and Substance P Receptor in Exercise

International Journal of Applied Physics and Mathematics, 2013
Dan Xu, Jimin Zhang, Xiyan Xie, Shun Li, Lijuan Hou   +4 more
openaire   +2 more sources

Olaparib synergy screen reveals Exemestane induces replication stress in triple‐negative breast cancer

Molecular Oncology, EarlyView.
Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh, Liping Su, Suet Lin Chia, Xiaohe Tian, Haslina Ahmad, Martin R. Gill   +5 more
wiley   +1 more source

Ferrocenyl-Substituted Curcumin Derivatives as Potential SHP‑2 Inhibitors for Anticolorectal Cancer: Design, Synthesis and In Vitro Evaluation

ACS Omega
Xing-Ze Zhang, Gen Li, Gao-Yong Hu, Chen-Lin Wang, Yu-Qiu Fang, Yuye Li, Xue-Jie Qi, Lili Duan   +7 more
doaj   +1 more source

The Role of <i>Substance P</i> in Corneal Homeostasis. [PDF]

Biomolecules
Jastrzębska-Miazga I, Machna B, Wyględowska-Promieńska D, Smędowski A.   +3 more
europepmc   +1 more source

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham, Jasibel Vasquez‐Gonzalez, Samantha M. Barnada, Salome Tchotorlishvili, Latese Jones, Ryan Maguire, Genevieve Lewis, Kinza Rizwan, Jenny Deng, Salma Koachar, Drithi Patel, Hailey Shankle, Tessa Mulders, Namra Ajmal, Charalambos Solomides, Emad S. Alnemri, Teresa F. Alnemri, Ayesha A. Shafi, Leonard G. Gomella, Wm Kevin Kelly, Steven B. McMahon, Matthew J. Schiewer   +21 more
wiley   +1 more source

Peripheral substance P induces deficits in hippocampal synaptic plasticity and memory. [PDF]

Mol Brain
Kim SY, Yoon KN, Ji J, Kim MG, Choi SA, Park G, Lee WW, Chung JH, Kim SJ, An JY, Lee DH, Lee YS.   +11 more
europepmc   +1 more source